These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Meredith RF Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435 [TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy for Non-Hodgkin's Lymphoma. Rao AV; Akabani G; Rizzieri DA Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070 [TBL] [Abstract][Full Text] [Related]
6. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary. Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924 [No Abstract] [Full Text] [Related]
7. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394 [TBL] [Abstract][Full Text] [Related]
8. [New trends in non-Hodgkin's lymphoma therapy]. Mazur G; Wróbel T; Jurczak W; Butrym A Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents. Pauwels EK; Erba P Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631 [TBL] [Abstract][Full Text] [Related]
11. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820 [TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Kawashima H ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Macklis RM Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Evens AM; Gordon LI Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144 [TBL] [Abstract][Full Text] [Related]
15. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792 [TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Hendrix CS; de Leon C; Dillman RO Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607 [TBL] [Abstract][Full Text] [Related]
17. New strategies in radioimmunotherapy for lymphoma. Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386 [TBL] [Abstract][Full Text] [Related]
18. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Meredith RF; Knox SJ Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433 [TBL] [Abstract][Full Text] [Related]
20. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Leonard JP; Siegel JA; Goldsmith SJ Cancer Invest; 2003 Apr; 21(2):241-52. PubMed ID: 12743990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]